- Home
- DT vs EXEL Comparison
DT vs EXEL Comparison
Compare DT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DT | EXEL |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 12.7B |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DT | EXEL |
|---|---|---|
| Price | $50.98 | $56.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 21 |
| Target Price | ★ $51.77 | $46.50 |
| AVG Volume (30 Days) | ★ 6.4M | 2.6M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | 0.12 | ★ 1.60 |
| Revenue | ★ $2,018,387,000.00 | $452,477,000.00 |
| Revenue This Year | $21.74 | $13.61 |
| Revenue Next Year | $14.85 | $13.13 |
| P/E Ratio | $417.25 | ★ $35.45 |
| Revenue Growth | ★ 18.82 | N/A |
| 52 Week Low | $31.64 | $33.76 |
| 52 Week High | $53.29 | $57.57 |
Technical Indicators
Market Signals| Indicator | DT | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.03 | 58.46 |
| Support Level | $42.56 | $54.30 |
| Resistance Level | $52.64 | $57.12 |
| Average True Range (ATR) | 1.76 | 1.42 |
| MACD | -0.06 | 0.44 |
| Stochastic Oscillator | 67.69 | 94.17 |
Price Performance
Historical ComparisonAbout DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.